All our 17 exceptional MTOR preceptors conduct leading-edge cancer research with a strong translational focus. The research interests of the MTOR faculty are diverse but inter-related as attested by numerous collaborations and common publications. The synergies between basic researchers and physicians are one of the major strengths of this program that will provide true hands-on training on translational research. Our roster of preceptors includes:
Effie Apostolou, Ph.D. focuses on pluripotency and somatic cell reprogramming.
Himisha Beltran, M.D. investigates mechanisms of treatment resistance in neuroendocrine prostate cancer. At the Englander Institute for Precision Medicine, she is developing platforms for biomarker development and clinical applications across tumor types.
John Blenis, Ph.D. investigates the role of signaling pathways and metabolic processes that are implicated in disease progression and development of drug resistance.
Lewis Cantley, Ph.D. focuses on the regulation of pancreatic cancer metabolism and the roles of the Mek and PI3 signaling pathways.
Leandro Cerchietti, M.D. is interested in experimental therapeutics and aspects of lymphoma biology.
Andrew Dannenberg, M.D. is exploring the link between menopause and obesity with breast cancer inflammation and the development and progression of breast cancer.
Lukas Dow, Ph.D. studies the initiation, progression and response of colorectal cancer using in vivo animal model systems and ex vivo organotypic cultures.
Olivier Elemento, Ph.D. is applying big data analytics to provide insights: in regulatory networks in cancer cells; in tumor genome evolution anticancer drug resistance; and genomics and epigenomics of tumors.
Paraskevi (Evi) Giannakakou, Ph.D. focuses on the mechanisms of action of drugs that affect microtubules, on androgen receptor signaling, and on developing novel assays for the molecular characterization of circulating tumor cells.
Monica Guzman, Ph.D. conducts research to identify novel targets in leukemia stem cells, and biomarkers for therapeutic interventions for acute and chronic myeloid leukemias.
Dan Avi Landau, M.D., Ph.D. is modeling somatic and tumor evolution aiming to therapies that anticipate and address tumor evolution.
Ari Melnick, M.D. is interested in therapeutic targeting of oncogenic transcription factors and in the transcriptional programming in malignant versus normal B-cells.
Shahin Rafii, M.D. is interested in stem cell biology and angiogenesis and currently is exploring the molecular and cellular mechanisms, which are involved in organ regeneration and tumor growth.
David Rickman, Ph.D. studies key oncogenic transcription factors in prostate cancer and mechanisms of treatment resistance.
Mark Rubin, M.D. focuses on the development of molecular biomarkers to distinguish indolent from aggressive prostate cancer.
Joseph Scandura, M.D. is developing new therapies for myeloid hematopoietic malignancies and he conducts research to understand how hematopoietic stem cell function contributes to malignant phenotypes such as acute leukemia.